Sinocare

Sinocare EBITDA per Share

The EBITDA per Share of Sinocare (300298.SZ) as of Oct 23, 2026 is 0.18 CNY. In the previous year, EBITDA per Share was 0.94 CNY — a change of -81.33% (lower).

EBITDA per Share

0.18CNY

YoY

-81.33%

Last updated:

EBITDA per Share of Sinocare is 2025 0.18 CNY. EBITDA per Share of Sinocare was 2024 0.94 CNY. It decreases by -81.33% lower compared to the previous year.

The Sinocare EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.62 CNY
Jan 1, 2019
0.56 CNY
Jan 1, 2020
0.72 CNY
Jan 1, 2021
0.37 CNY
Jan 1, 2022
0.91 CNY
Jan 1, 2023
0.72 CNY
Jan 1, 2024
0.94 CNY
Jan 1, 2025
0.18 CNY
The Sinocare EBITDA per Share history
YEAREBITDA per ShareYoY
0.18CNY-81.33%
0.94CNY+29.86%
0.72CNY-20.25%
0.91CNY+144.54%
0.37CNY-48.61%
0.72CNY+28.63%
0.56CNY-9.58%
0.62CNY+5.53%
0.59CNY+258.00%
0.16CNY-43.64%
0.29CNY-28.71%
0.41CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocare Stock analysis

What does Sinocare do? Sinocare, Inc. generates revenue through the development, production, and sale of chronic disease rapid detection products, primarily focusing on blood sugar monitoring systems. The company offers blood sugar testing instruments, related strips, blood sugar testing systems, and mobile blood sugar instruments under its SANNUO brand. These products are sold domestically and internationally, targeting healthcare providers and consumers managing diabetes. Sinocare also provides diabetes management information systems as part of its product portfolio. The SANNUO brand is central to Sinocare's sales strategy, with products distributed across domestic and overseas markets. The company's offerings include micro blood instant blood sugar monitoring systems, which are designed for chronic disease management. Sinocare's revenue streams are derived from direct sales of these medical devices and associated information systems to end-users and healthcare institutions. Sinocare's business model relies on the consistent demand for diabetes management solutions, with its SANNUO-branded products serving both individual consumers and healthcare facilities. The company's product range includes blood sugar testing instruments, strips, and mobile blood sugar instruments, all marketed under the SANNUO label. These products are distributed globally, supporting Sinocare's revenue generation through direct sales channels. Sinocare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocare stock

EBITDA per Share of Sinocare is 0.18 CNY in 2025.

EBITDA per Share of Sinocare changed from 0.94 CNY to 0.18 CNY, representing a -81.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Sinocare since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sinocare

All Key Metrics — Sinocare